Walmart to Replace AstraZeneca in Nasdaq-100 Index on January 20
Overview
Walmart is set to join the prestigious Nasdaq-100 Index, replacing AstraZeneca effective January 20. This move follows Walmart's decision to shift its primary stock listing from the New York Stock Exchange to the Nasdaq. The change impacts the Nasdaq-100, Nasdaq-100 Equal Weighted, and Nasdaq-100 Ex-Tech Sector indices.
Index Shakeup
Walmart is poised to enter the Nasdaq-100 Index next week, replacing the British pharmaceutical giant AstraZeneca. The change becomes effective before market open on January 20. This inclusion follows Walmart's significant decision announced in November to transfer its long-standing listing from the New York Stock Exchange (NYSE) to its primary competitor, Nasdaq.
Reasons for the Move
Companies often switch exchanges to better align with an exchange's investor base, technology, and service offerings, or to manage listing and compliance costs. The Nasdaq-100, which tracks 100 of the largest non-financial companies on the Nasdaq platform, including tech leaders like Nvidia and Apple, has proven increasingly attractive. This appeal likely factored into Walmart's strategic decision.
Broad Index Impact
Walmart's addition will not be limited to the main Nasdaq-100 Index. It will also replace AstraZeneca in the Nasdaq-100 Equal Weighted Index and the Nasdaq-100 Ex-Tech Sector Index. Nasdaq confirmed the adjustments will take place prior to the market's opening on January 20.
